Xirun Wan

Xirun Wan

Auto-generated profile, based on publicly available information

Xirun Wan

National Clinical Research Center for Women’s Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2022 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
MJMingliang Ji
Mingliang Ji
SJShiyang Jiang
Shiyang Jiang
JZJun Zhao
Jun Zhao
XWXirun Wan
Xirun Wan
FFFengzhi Feng
Fengzhi Feng
YXYang Xiang
Yang Xiang

1 January 2022 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
YLYuan Li
Yuan Li
WWWeidi Wang
Weidi Wang
XWXirun Wan
Xirun Wan
FFFengzhi Feng
Fengzhi Feng
YHYonglan He
Yonglan He
YXYang Xiang
Yang Xiang
Li Y, et al. J Gynecol Oncol. 2022 Jan;33(3):e33. https://doi.org/10.3802/jgo.2022.33.e33

1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
JZJiayuan Zhao
Jiayuan Zhao
DWDan Wang
Dan Wang
YHYonglan He
Yonglan He
XWXirun Wan
Xirun Wan
JZJun Zhao
Jun Zhao
YXYang Xiang
Yang Xiang
Zhao J, et al. J Gynecol Oncol. 2025 May;36:e130. https://doi.org/10.3802/jgo.2025.36.e130

1 June 2026 in JCO Precision Oncology
Verified
Journal Article
Open access
WWWeidi Wang
Weidi Wang
YJYunshu Jiao
Yunshu Jiao
YLYuan Li
Yuan Li
FJFang Jiang
Fang Jiang
XWXirun Wan
Xirun Wan
YXYang Xiang
Yang Xiang
PURPOSE: Current prognostic systems are inadequate for intermediate trophoblastic tumors (ITTs). The aim of this study was to develop a machine learning (ML)-based model to predict progression-free survival (PFS) in patients with ITT and implement a web-based tool for individualized risk stratification. MATERIALS AND METHODS: We analyzed a retrospective cohort of 236 patients with ITT treated at a national tertiary center between 2000 and 2024. A multimodal feature selection strategy—integrating Cox regression, LASSO, Gradient Boosting Machine (GBM), and Random Survival Forest (RSF)—was used to identify robust predictors from clinicopathologic and inflammatory variables. The final prognostic model was constructed using the RSF approach. Model performance was evaluated through a rigorous nested 5-fold cross-validation framework to prevent data leakage. RESULTS: Five key predictors were identified: International Federation of Gynecology and Obstetrics stage, interval from antecedent pregnancy, Ki-67 index, neutrophil-to-lymphocyte ratio, and systemic immune-inflammation index. The RSF model demonstrated robust discrimination with a cross-validated concordance index of 0.816 (95% CI, 0.721 to 0.895) and excellent calibration (Integrated Brier Score, 0.113). Decision-curve analysis confirmed clinical utility within the relevant 20%-60% threshold range. An interactive web tool (Shinyapps) was deployed to generate real-time individualized PFS predictions with 95% confidence intervals. CONCLUSION: To our knowledge, this study presents the first ML-based prognostic model specifically for ITT. By integrating immune-inflammatory markers with traditional clinicopathologic features, the RSF model offers superior risk stratification compared with anatomic staging or alternative models. The developed online tool serves as a proof-of-concept prototype to facilitate future external validation and research on personalized clinical decision making for this rare malignancy.